Win Min Oo, Ali Mobasheri & David J Hunter (2022) A narrative review of anti-obesity medications for obese patients with osteoarthritis, Expert Opinion on Pharmacotherapy, 23:12, 1381-1395, DOI: 10.1080/14656566.2022.2104636
A narrative review of anti-obesity medications for obese patients with osteoarthritis
|Author:||Oo, Win Min1,2; Mobasheri, Ali3,4,5,6; Hunter, David J1,7|
1Rheumatology Department, Royal North Shore Hospital, and Institute of Bone and Joint Research, Kolling Institute, Faculty of Medicine and Health, The University of Sydney, Sydney, Australia
2Department of Physical Medicine and Rehabilitation, Mandalay General Hospital, University of Medicine, Mandalay, Myanmar
3Research Unit of Medical Imaging, Physics and Technology, Faculty of Medicine, University of Oulu, Oulu, Finland
4Department of Regenerative Medicine, State Research Institute Centre for Innovative Medicine, Vilnius, Lithuania
5Department of Joint Surgery, First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China
6World Health Organization Collaborating Centre for Public Health Aspects of Musculoskeletal Health and Aging, Liege, Belgium
7Clinical Research Centre, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, China
|Persistent link:|| http://urn.fi/urn:nbn:fi-fe2023030930851
|Publish Date:|| 2023-07-27
Introduction: The prevalence of both obesity and osteoarthritis (OA) is increasing worldwide (twindemic), and the association between the two chronic diseases is also well established.
Areas covered: In this narrative review, we will briefly describe the double burdens of both diseases, the impact of weight loss or gain on OA incidence and structural progression and discuss the biomechanical and anti-inflammatory mechanisms mediating these effects. FDA-approved anti-obesity drugs are summarized in terms of their clinical efficacy and safety profile, and the completed or ongoing phase 2/3 clinical trials of such drugs in OA patients with obesity are examined.
Expert opinion: We will discuss the perspectives related to principles of prescription of anti-obesity drugs, the potential role of phenotype-guided approach, time to drug effects in clinical trials, sustainability of weight loss based on the real-world studies, the importance of concomitant therapies, such as dieting and exercises, and the role of weight loss on non-weight bearing OA joints. Although obesity is the major risk factor for OA pathogenesis and progression, and there are a variety of anti-obesity medications on the market, research on the use of these disease-modifying drugs in OA (DMOAD) is still sparse.
Expert opinion on pharmacotherapy
|Pages:||1381 - 1395|
|Type of Publication:||
A2 Review article in a scientific journal
|Field of Science:||
3121 General medicine, internal medicine and other clinical medicine
DJ Hunter is supported by an NHMRC Investigator Grant. A Mobasheri is supported by the Academy of Finland Profi6 336449 grant awarded to the University of Oulu, the European Commission and the European Structural and Social Funds (ES Struktūrinės Paramos) awarded through the Research Council of Lithuania (Lietuvos Mokslo Taryba) and the funding programme: Attracting Foreign Researchers for Research Implementation (2018-2022), Grant No 01.2.2-LMT-K-718-02-0022.
© Expert Opinion on Pharmacotherapy. This is an Accepted Manuscript version of the following article, accepted for publication in Expert Opinion on Pharmacotherapy. Win Min Oo, Ali Mobasheri & David J Hunter (2022) A narrative review of anti-obesity medications for obese patients with osteoarthritis, Expert Opinion on Pharmacotherapy, 23:12, 1381-1395, DOI: 10.1080/14656566.2022.2104636. It is deposited under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.